Coherus BioSciences Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Coherus BioSciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Coherus BioSciences stock.
View analyst ratings for Coherus BioSciences or view top-rated stocks.

Wall Street analysts have given Coherus BioSciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Coherus BioSciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Coherus BioSciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Coherus BioSciences.

Coherus BioSciences, Inc. (NASDAQ:CHRS) issued its quarterly earnings data on Thursday, May, 6th. The biotechnology company reported ($2.37) earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by $2.46. The biotechnology company earned $83.03 million during the quarter, compared to analysts' expectations of $97.87 million. Coherus BioSciences had a negative trailing twelve-month return on equity of 34.76% and a negative net margin of 17.23%.
View Coherus BioSciences' earnings history.

Coherus BioSciences' stock was trading at $15.87 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CHRS stock has decreased by 9.4% and is now trading at $14.38.
View which stocks have been most impacted by COVID-19.

5 analysts have issued twelve-month target prices for Coherus BioSciences' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Coherus BioSciences' stock price to reach $24.83 in the next twelve months. This suggests a possible upside of 72.7% from the stock's current price.
View analysts' price targets for Coherus BioSciences or view top-rated stocks among Wall Street analysts.

21 employees have rated Coherus BioSciences CEO Dennis M. Lanfear on Glassdoor.com. Dennis M. Lanfear has an approval rating of 95% among Coherus BioSciences' employees. This puts Dennis M. Lanfear in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Coherus BioSciences include Abcam (ABCM), Sana Biotechnology (SANA), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Relay Therapeutics (RLAY), BioCryst Pharmaceuticals (BCRX), Bavarian Nordic A/S (BVNRY), Vericel (VCEL), NanoString Technologies (NSTG), Revolution Medicines (RVMD), Sorrento Therapeutics (SRNE) and Editas Medicine (EDIT).
View all of CHRS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus BioSciences investors own include Halozyme Therapeutics (HALO), Chembio Diagnostics (CEMI), Exelixis (EXEL), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Intelsat (I), Idera Pharmaceuticals (IDRA), Immunomedics (IMMU), Sangamo Therapeutics (SGMO) and Viking Therapeutics (VKTX).

Coherus BioSciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus BioSciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.33%), JPMorgan Chase & Co. (6.86%), Perceptive Advisors LLC (6.20%), Alliancebernstein L.P. (5.74%), Aristotle Capital Boston LLC (2.77%) and Goldman Sachs Group Inc. (1.76%). Company insiders that own Coherus BioSciences stock include Dennis M Lanfear, James Healy, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Mcdavid Stilwell, Vincent R Anicetti and Vladimir Vexler.
View institutional ownership trends for Coherus BioSciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including UBS Asset Management Americas Inc., Ameriprise Financial Inc., Alliancebernstein L.P., Barclays PLC, Janus Henderson Group PLC, Teachers Retirement System of The State of Kentucky, Royce & Associates LP, and Redwood Investments LLC. Company insiders that have sold Coherus BioSciences company stock in the last year include Dennis M Lanfear, Jean-Frederic Viret, Mary T Szela, Mats Wahlstrom, Vincent R Anicetti, and Vladimir Vexler.
View insider buying and selling activity for Coherus BioSciences or view top insider-selling stocks.

CHRS stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Scout Investments Inc., Millennium Management LLC, Platinum Investment Management Ltd., Aristotle Capital Boston LLC, Brown Advisory Inc., JPMorgan Chase & Co., and Citigroup Inc..
View insider buying and selling activity for Coherus BioSciences or or view top insider-buying stocks.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CHRS stock can currently be purchased for approximately $14.38.

Coherus BioSciences has a market capitalization of $1.09 billion and generates $475.82 million in revenue each year. The biotechnology company earns $132.24 million in net income (profit) each year or $1.62 on an earnings per share basis.

Coherus BioSciences employs 310 workers across the globe.

The official website for Coherus BioSciences is www.coherus.com.

Coherus BioSciences is headquartered at 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065.

Coherus BioSciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]